abstract
- We spotlight the promising preliminary findings reported by Goldsmith et al. of a phase 1 first-in-child study showcasing the safety and efficacy of lorlatinib against treatment-refractory or relapsed ALK-driven neuroblastoma.1.
Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
authors
status
publication date
- June 2023
has subject area
- Anaplastic Lymphoma Kinase (MeSH)
- Carcinoma, Non-Small-Cell Lung (MeSH)
- Humans (MeSH)
- Lactams, Macrocyclic (MeSH)
- Lung Neoplasms (MeSH)
- Neoplasm Recurrence, Local (MeSH)
- Neuroblastoma (MeSH)
- Protein Kinase Inhibitors (MeSH)
published in
- Cell Reports Medicine Journal